Bio-View Statistics

Total Valuation

Bio-View has a market cap or net worth of ILS 37.47 million. The enterprise value is 23.47 million.

Market Cap	37.47M
Enterprise Value	23.47M

Important Dates

The next estimated earnings date is Wednesday, March 26, 2025.

Earnings Date	Mar 26, 2025
Ex-Dividend Date	n/a

Share Statistics

Bio-View has 127.01 million shares outstanding. The number of shares has decreased by -28.39% in one year.

Current Share Class	n/a
Shares Outstanding	127.01M
Shares Change (YoY)	-28.39%
Shares Change (QoQ)	-6.19%
Owned by Insiders (%)	53.96%
Owned by Institutions (%)	9.77%
Float	51.90M

Valuation Ratios

The trailing PE ratio is 48.38.

PE Ratio	48.38
Forward PE	n/a
PS Ratio	1.16
PB Ratio	1.35
P/TBV Ratio	1.28
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 12.03, with an EV/FCF ratio of -17.92.

EV / Earnings	26.46
EV / Sales	0.68
EV / EBITDA	12.03
EV / EBIT	260.82
EV / FCF	-17.92

Financial Position

The company has a current ratio of 2.89, with a Debt / Equity ratio of 0.10.

Current Ratio	2.89
Quick Ratio	2.09
Debt / Equity	0.10
Debt / EBITDA	1.44
Debt / FCF	-2.14
Interest Coverage	0.26

Financial Efficiency

Return on equity (ROE) is 3.06% and return on invested capital (ROIC) is 0.17%.

Return on Equity (ROE)	3.06%
Return on Assets (ROA)	0.13%
Return on Capital (ROIC)	0.17%
Revenue Per Employee	1.04M
Profits Per Employee	26,879
Employee Count	33
Asset Turnover	0.81
Inventory Turnover	1.76

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -90.78% in the last 52 weeks. The beta is 0.35, so Bio-View's price volatility has been lower than the market average.

Beta (5Y)	0.35
52-Week Price Change	-90.78%
50-Day Moving Average	27.80
200-Day Moving Average	27.70
Relative Strength Index (RSI)	59.90
Average Volume (20 Days)	317,581

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Bio-View had revenue of ILS 34.34 million and earned 887,000 in profits. Earnings per share was 0.01.

Revenue	34.34M
Gross Profit	22.28M
Operating Income	90,000
Pretax Income	1.40M
Net Income	887,000
EBITDA	452,000
EBIT	90,000
Earnings Per Share (EPS)	0.01

Full Income Statement

Balance Sheet

The company has 16.80 million in cash and 2.80 million in debt, giving a net cash position of 13.99 million or 0.11 per share.

Cash & Cash Equivalents	16.80M
Total Debt	2.80M
Net Cash	13.99M
Net Cash Per Share	0.11
Equity (Book Value)	29.27M
Book Value Per Share	0.22
Working Capital	22.08M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -1.25 million and capital expenditures -60,000, giving a free cash flow of -1.31 million.

Operating Cash Flow	-1.25M
Capital Expenditures	-60,000
Free Cash Flow	-1.31M
FCF Per Share	-0.01

Full Cash Flow Statement

Margins

Gross margin is 64.86%, with operating and profit margins of 0.26% and 2.58%.

Gross Margin	64.86%
Operating Margin	0.26%
Pretax Margin	4.09%
Profit Margin	2.58%
EBITDA Margin	1.32%
EBIT Margin	0.26%
FCF Margin	n/a

Dividends & Yields

Bio-View does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	28.39%
Shareholder Yield	28.39%
Earnings Yield	n/a
FCF Yield	n/a

Stock Splits

The last stock split was on December 24, 2023. It was a forward split with a ratio of 10.

Last Split Date	Dec 24, 2023
Split Type	Forward
Split Ratio	10

Scores

Bio-View has an Altman Z-Score of 2.62. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.62
Piotroski F-Score	n/a